StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
AXSMBullishCorporate Developmentsnews
High materiality9/10

FDA Fast-Tracks Axsome's Alzheimer's Agitation Drug, Stock Soars

Dec 31, 2025, 10:51 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The FDA's Priority Review and strong clinical data enhance AXSM's market potential. Historical examples show similar scenarios have led to price surges.

AI summary

What happened, with direct paths to the underlying reporting

FDA accepted AXSM's supplemental NDA for AXS-05 for Alzheimer's agitation. Priority Review designation aims to expedite the review to six months. AXSM shares rose 18.18%, reaching a new 52-week high at $175.84. Needham raised AXSM's price target from $154 to $169, maintaining a Buy rating. Formal pre-NDA meeting minutes received for AXS-12's submission in narcolepsy.

  • FDA accepted AXSM's supplemental NDA for AXS-05 for Alzheimer's agitation.
  • Priority Review designation aims to expedite the review to six months.
  • AXSM shares rose 18.18%, reaching a new 52-week high at $175.84.
  • Needham raised AXSM's price target from $154 to $169, maintaining a Buy rating.
  • Formal pre-NDA meeting minutes received for AXS-12's submission in narcolepsy.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event